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Guidelines for Using 
HIV Testing Technologies 
in Surveillance
 
As the HIV/AIDS epidemic imposes an ever-larger burden globally,
surveillance for HIV becomes more critical in order to understand the
trends of the epidemic and to make sound decisions on how best to
respond to it. This is especially true in developing countries, which
account for a disproportionate share of new and long-standing infections.
To help countries focus their surveillance activities in the context of their
epidemic state (low-level, concentrated, or generalized), the World Health
Organization (WHO) and the Joint United Nations Programme on HIV/
AIDS (UNAIDS) have developed a conceptual framework to improve HIV
surveillance—second generation HIV surveillance. Guidelines for second
generation HIV surveillance suggest approaches to make better use of data
to increase and improve the response to the HIV epidemic. As biological
surveillance (serosurveillance) is an important component of most HIV
surveillance activities, an understanding of current HIV testing technolo-
gies is important.
In the context of second generation HIV surveillance, these labora-
tory guidelines suggest methods for selecting, evaluating, and implement-
ing HIV testing technologies and strategies based on a country’s
laboratory infrastructure and surveillance needs. The guidelines provide
recommendations for specimen selection, collection, storage, and testing
and for the selection and evaluation of appropriate HIV testing strategies
and technologies to meet surveillance objectives. Quality assurance issues
are also addressed.
These technical guidelines are written for HIV surveillance coordi-
nators and other health professionals involved in HIV testing for surveil-
lance purposes in developing countries. They are part of a series of
operational guidelines for second generation HIV surveillance systems. 
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1.0 Introduction
 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organi-
zation (WHO) recommend the use of second generation HIV surveillance to improve collection,
analysis, and use of data essential to AIDS control programs. The use of second generation HIV
surveillance is also promoted to help national and international institutions monitor the epidemic
and guide their responses to it (UNAIDS/WHO 2000). Using second generation HIV surveillance
approaches, surveillance systems should be ﬂexible in order to change with a country’s needs and
state of the epidemic: low-level, concentrated, or generalized (Box 1) (UNAIDS/WHO 2000). As
countries develop or enhance their surveillance programs using the principles of second genera-
tion HIV surveillance, the surveillance data collected can be better used for the purposes
described above. 
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Topics Addressed in These Guidelines
 
• Specimen Selection, Collection, Storage, and Testing
• HIV Testing Technologies and Strategies
• Selecting and Evaluating Testing Technologies
• Quality Assurance Measures
 
Box 1. Three different epidemic states
 
Low-level epidemic: 
 
The epidemic state in which HIV has never spread to signiﬁcant levels in 
any subpopulation, although HIV infection may have existed for many years. (HIV prevalence has 
not consistently exceeded 5% in any deﬁned subpopulation.)
 
Concentrated epidemic: 
 
The epidemic state in which HIV has spread rapidly in a deﬁned 
subpopulation but is not well-established in the general population. (HIV prevalence is 
consistently >5% in at least one deﬁned subpopulation and is <1% in pregnant women in urban 
areas.)
 
 
Generalized epidemic: 
 
The epidemic state in which HIV is ﬁrmly established in the general 
population. (HIV prevalence is consistently >1% in pregnant women.)
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Second generation HIV surveillance relies on data collected from biological surveillance
(serosurveillance), behavioral surveillance, and other sources (e.g., HIV/AIDS case surveillance,
death registration, sexually transmitted infection surveillance, tuberculosis surveillance) to
describe a country’s HIV epidemic and respond effectively. It aims to improve integration of data
from these sources. It also supports continuous research into new epidemiologic tools; improved
methods for building estimates and modeling the epidemic; and better ways for using data for
advocacy, planning, monitoring, and evaluation. 
HIV serosurveillance
 
 
 
data are used to estimate HIV prevalence rates and geographic distri-
bution of infection, monitor trends over time in speciﬁc population groups, and identify subpop-
ulations at increased risk for infection. This information is then used to assist countries’ efforts to
set HIV policy and priorities, plan and evaluate prevention programs, and evaluate the effective-
ness of the countries’ response to the epidemic.
As biological surveillance is the primary method for determining HIV prevalence rates
locally or nationally, accurate HIV testing is critical for second generation HIV surveillance. With
advances in diagnostic immunology, HIV testing technologies have improved greatly. Currently
available enzyme immunoassays (EIAs) are more accurate than earlier generations of EIAs, and
the latest generation of HIV rapid tests can provide results similar to EIAs in less than 45 minutes
with minimal experience and no equipment. These rapid tests enable testing for HIV surveillance
activities in areas where testing could not previously occur (e.g., areas with limited laboratory
resources) and for hard-to-reach populations (e.g., female sex workers) who may not be accessible
through clinical services. 
These guidelines provide guidance on types of specimens to collect and how to store and
test them. They describe HIV testing strategies recommended by WHO, which are based on HIV
prevalence rates, and existing HIV testing technologies used for biological surveillance. They also
include information regarding strategies and technologies for use in diagnostic testing since data
from diagnostic testing may also be used as a source of surveillance information. They outline
methods for selecting and evaluating testing technologies appropriate to a country’s epidemic
state and needs. Because accurate results are important in biological surveillance for HIV, quality
assurance measures are also addressed. The guidelines also include a glossary of terms used in the
document. These technical guidelines are written for HIV surveillance coordinators and other
health professionals involved in HIV testing for surveillance purposes in developing countries.
They are part of a series of operational guidelines for second generation HIV surveillance systems.
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2.0 Overview of HIV Testing in 
HIV Serosurveillance 
 
In order to appreciate the context of these guidelines, it is important to understand the
objectives of conducting HIV testing, different testing approaches used in serosurveillance, and
populations tested.
 
2.1 Objectives of HIV Testing
 
HIV testing can be conducted for surveillance, diagnosis, or blood screening (UNAIDS/WHO
1998). In developing countries, most HIV testing for surveillance purposes is conducted as part of
seroprevalence surveys among population groups such as women attending antenatal clinics,
patients with sexually transmitted infections, female sex workers, or injection drug users. In addi-
tion, the results of testing for diagnostic purposes (e.g., in voluntary counseling and testing clin-
ics) and for blood screening purposes (e.g., in blood donors), as well as results of regular testing
of other groups (e.g., military recruits), can provide additional prevalence data for surveillance
purposes. These data from diagnostic testing, blood screening, and regular HIV testing of other
groups should not be extrapolated to the general population because they contain inherent biases. 
 
2.2 HIV Testing Approaches
 
The selection of HIV testing approaches for serosurveillance depends on contextual factors,
such as country policies and, given the epidemic state, appropriate population groups and set-
tings for HIV testing. Unlinked anonymous HIV testing (without informed consent) is only con-
ducted in clinic settings where blood is collected regularly for other purposes (usually syphilis
testing) (Box 2). If feasible, such testing should be conducted in settings where referrals to volun-
tary counseling and testing are provided. Linked testing (conﬁdential or anonymous) with
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Overview of HIV Testing in HIV Serosurveillance
 
• HIV Testing Objectives
 
Surveillance
Diagnosis
Blood Screening
 
• HIV Testing Approaches
 
Unlinked Testing
Linked Testing
 
• Populations Surveyed
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informed consent is the preferred approach when the specimens are collected solely for HIV test-
ing, for example, HIV surveillance in populations not accessible through clinic settings (e.g.,
hard-to-reach populations such as injection drug users, female sex workers, and men who have
sex with men) (Box 2). When specimens are collected solely for HIV testing, unlinked anonymous
testing with informed consent may also be used, depending on the country’s relevant policies and
guidelines.
When informed consent is required (Box 2), it must be obtained before testing the specimen
for HIV, following the country’s relevant policies and guidelines. Whenever informed consent is
obtained, participation bias is an important issue and should be assessed and taken into consider-
ation in the analysis. 
A code should be assigned to every specimen tested for HIV. The code is used to identify
each specimen during testing procedures. It is unique to a specimen, and it may or may not be
linked to personal identifying information (e.g., name, clinic identiﬁcation number), depending
on whether the HIV testing is linked or unlinked. The code can be linked to demographic (e.g.,
age, sex, marital status, geographic area of residence) (in linked and unlinked testing) and risk
behavior information (in linked testing) that is obtained at the time the specimen is collected.
 
a
 
The use of this method is described by the UNAIDS/WHO Working Group on Global HIV/AIDS/STI Surveillance; its use in 
HIV surveillance activities should be guided by the policies of the country in which these activities are carried out. 
 
b 
 
Informed consent is based on the principle that competent persons are entitled to make decisions regarding their 
participation in, or acquiescence to, certain events in the context of a professional relationship between health-care 
provider and patient/client. Informed consent protects the person’s freedom of choice and respects his/her autonomy, 
particularly with regard to decisions affecting his/her body and health.
(Adapted from WHO/Global Programme on AIDS 1992)
 
Box 2. Linked and unlinked HIV testing
 
Unlinked anonymous testing (without informed consent)
 
• Testing of unlinked specimens collected for other purposes
• No personal identiﬁers or names obtained, no informed consent, no counseling required
• Coded specimen
 
Unlinked anonymous testing (with informed consent)
 
a
 
• Testing of unlinked specimens collected solely for surveillance purposes
• Informed consent
 
b 
 
required
• No personal identiﬁers or names obtained, no counseling required
• Coded specimen
 
Linked conﬁdential testing (with informed consent)
 
• Informed consent
 
b
 
 and pretest and posttest counseling required
• Personal identiﬁers or names obtained
• Coded specimen; code linked to personal identifying information
 
Linked anonymous testing (with informed consent)
 
• Informed consent
 
b
 
 and pretest and posttest counseling required
• No personal identiﬁers or names obtained
• Coded specimen; code given to patient so that only patient can link himself or herself to 
results
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Unlinked anonymous testing (Figure 2.1)
 
 without informed consent is only conducted in
clinical settings in which a specimen of blood originally collected for other purposes, such as
syphilis testing at antenatal clinics, is tested for HIV after all information that could identify the
source of the blood is removed from the specimen. Thus, the test result may not be traced back to
the patient nor may he or she be informed of the test results.
 
Figure 2.1 Unlinked Anonymous HIV Testing
 
*Staff members #1 and #2 should not be the same person so that the patient’s anonymity is ensured.
 
To ensure patient anonymity at the clinic and laboratory, one staff member should collect
the specimen and a different staff member should perform testing. One staff member (clinician or
laboratory technician) should collect and process the specimen for routine clinical testing and for
unlinked anonymous HIV testing. The processing of the specimen for unlinked anonymous HIV
testing requires removing an aliquot of blood and placing it into a new tube that is labeled with a
new code not linked to any personal identifying information. Another staff member should per-
form unlinked anonymous HIV testing.
In some settings, one staff member (the laboratory technician) is responsible for both col-
lecting the specimen and performing unlinked anonymous HIV testing. In these situations, it is
suggested that another staff member process the specimen for unlinked anonymous testing (i.e.,
remove an aliquot of blood and place it in a new tube labeled with a new code not linked to any
personal identifying information). 
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At the time of specimen collection, a staff member collects demographic information (e.g.,
age, sex, marital status, geographic area of residence) and medical history from the patient. This
information is recorded onto a clinic form along with the code on the specimen (e.g., name, clinic
identiﬁcation number). After the specimen is processed for unlinked anonymous HIV testing and
the aliquot is labeled with a new code, the same staff member records the new code onto a sur-
veillance form and abstracts the needed demographic information (e.g., age, sex, marital status)
onto the form. This abstracted information is therefore not linked to any personal identifying
information. The unlinked anonymous HIV test results can then be matched with the demo-
graphic information for analysis by the new code. It is important that the anonymity of the spec-
imen not be compromised by the collection of too much demographic information that may allow
identiﬁcation of individuals.
In settings where blood is not routinely collected for other purposes, unlinked anonymous
testing without informed consent is considered unethical. Therefore, in these situations, linked
testing with free access to voluntary counseling and testing should be provided, or, if country
policy permits, unlinked anonymous testing with informed consent should be conducted.
In unlinked anonymous testing with informed consent, the participant is asked whether he
or she would agree to participate in the HIV surveillance study and informed that the results of
the HIV test performed will be unlinked by removing all personal identifying information from
the specimen. Therefore, it will not be possible to trace which participants have positive test
results. The participant should be provided free access to HIV testing and counseling. The person
can refuse to participate in the study, thereby introducing a possible participation bias. 
 
Linked testing (Figure 2.2) 
 
involves linking the results of the HIV test with the person
tested and allows the person to receive his or her HIV test results. This method requires obtaining
informed consent and providing pretest and posttest counseling. Linked testing may or may not
occur in a clinical setting. Linked testing can be either conﬁdential or anonymous. Since the per-
son tested may receive the test results, linked testing requires additional conﬁrmatory HIV test-
ing.
In linked conﬁdential testing, a person agrees to have an HIV test with the assurance that
the test result will be kept conﬁdential and only selected health-care providers may be informed.
HIV test results can be matched to the person by a code linked to personal identifying informa-
tion. For linked conﬁdential testing, a staff member obtains informed consent and provides pre-
test counseling prior to specimen collection. The specimen is then labeled with a code that can be
linked to personal identifying information (e.g., name, clinic identiﬁcation number). After linked
conﬁdential HIV testing is performed, the test results are given to the person, along with posttest
counseling. 
In linked anonymous testing, a person consents to having an HIV test. The methods for col-
lecting and processing the specimen are the same as for linked conﬁdential testing. However, the
specimen is labeled with a code not linked to any personal identifying information, and only the
person can link himself or herself to the test result. 
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Figure 2.2 Linked Conﬁdential and Anonymous HIV Testing
 
2.3 Populations Surveyed 
 
The state of the epidemic determines which population groups are surveyed. Countries with
generalized epidemics conduct sentinel serosurveillance primarily among pregnant women at
antenatal clinics as the basis of their surveillance systems. Serosurveillance is typically conducted
in large clinics, outpatient clinics at hospitals, or health centers. Countries with concentrated epi-
demics or low-level epidemics focus primarily on speciﬁc population groups who are perceived to
be at high risk for infection, for example, female sex workers and their clients, injection drug
users, or men who have sex with men. Therefore, venues attended by such persons are selected as
sentinel sites; these may include clinics that treat sexually transmitted infections, drug treatment
centers, correctional facilities, brothels, bars, and clubs. Other populations surveyed can include
(1) military recruits or conscripts and (2) occupational groups at increased risk for infection, such
as factory workers, miners, or migrant workers. The prevalence rates determined for these speciﬁc
population groups should be applied only to the group studied, not to the general population.
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Further discussion of the methods used for the selection and sampling of appropriate sub-
groups and sites for conducting HIV surveillance activities are beyond the scope of this docu-
ment.
 
2.4 Measuring HIV Incidence
 
The recent modiﬁcation of a type of HIV test termed “detuned assay” or Standardized Test-
ing Algorithm for Recent HIV Seroconversion (STARHS) is now available only as a research tool
for measuring HIV incidence (rate of new HIV infections). Its use in nonresearch settings has not
been approved in any country. However, because further development is under way for its use in
the ﬁeld as a surveillance tool, it is brieﬂy described here.
STARHS allows for determining whether an HIV-infected person has been recently infected.
Speciﬁcally, it indicates whether the person has seroconverted (produced HIV antibodies) within
an average of about 130 days prior to being tested (Janssen et al. 1998). This ability to distinguish
recent from older infections permits estimation of recent HIV incidence based on a single cross-
sectional survey. Such estimates of HIV incidence can be extremely valuable for evaluating the
current trends of HIV infection. 
 
recommendation
 
• If the epidemic is generalized, antenatal clinics are preferred sites for serosurveillance. 
• If the epidemic is concentrated or low-level, the surveillance system should focus on 
populations at increased risk (e.g., female sex workers and their clients, injection drug users, 
and men who have sex with men).
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3.0 Specimens Used in HIV Testing
 
Many types of specimens can be used with HIV testing technologies for HIV biological sur-
veillance: whole blood, plasma, serum, oral ﬂuids, and urine. The choice of specimen collected
depends on logistics, populations and sites selected, and the HIV testing strategy. Specimens must
be collected, tested, and stored in an appropriate manner in order to obtain accurate and reliable
results.
For serosurveillance activities, specimens are usually collected and stored prior to HIV test-
ing at a regional or national laboratory. Serum, plasma, and dried blood spots can be stored and
tested at a later date; speciﬁcations for storage will depend on the type of specimen collected.
Specimens not tested on site at the local level will need to be transported to a regional or
national laboratory for testing. The methods by which specimens are transported will depend on
the country’s infrastructure. Few countries may have courier systems linking health-care facilities
and laboratories. More frequently, the ﬁeld surveillance staff members themselves transport the
specimens from the local to the national laboratory. 
 
3.1 Specimen Selection
 
3.1.1 Advantages and Disadvantages of Whole Blood, Serum, 
and Plasma
 
Whole blood, serum, and plasma, which can be collected by venipuncture or ﬁnger stick
(see 3.2), have the following advantages and disadvantages in HIV testing: 
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Specimens Used in HIV Testing
 
• Selecting Specimens
 
Advantages and Disadvantages of Whole Blood, Serum, and Plasma
Advantages and Disadvantages of Urine and Oral Fluids
 
• Collecting, Processing, and Storing Blood Specimens
• Collecting and Storing Urine and Oral Fluids
• Labeling and Logging Specimens
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Advantages
 
• Have higher concentrations of HIV antibodies than urine or oral ﬂuids (Rose et al.
1997).
• Have potential for additional routine testing (e.g., syphilis, hepatitis B, hepatitis C) from
a single specimen.
• Have potential for special studies (e.g., HIV typing [HIV-1 vs. HIV-2], HIV subtyping,
antiretroviral resistance).
• Are easy to collect and test in clinical settings with a laboratory and a trained
phlebotomist.
• Are easy to collect in nonclinical settings (whole blood from ﬁnger stick).     
 
Disadvantages
 
• Require invasive collection technique.
• Require skilled technician (for collecting and processing serum or plasma).
• Compared with urine and oral ﬂuids, require more equipment (e.g., needles, tubes, or
lancets) and biohazard waste facilities.
• Is difﬁcult to collect serum or plasma in nonclinical settings if venipuncture is required.
• Compared with oral ﬂuids, pose a greater risk to health-care workers and technicians
through inadvertent exposure, both because of higher antibody concentrations and the
use of sharp collecting devices.
 
3.1.2 Advantages and Disadvantages of Urine and Oral Fluids
 
Other specimens besides blood and blood products can be used for HIV testing. For linked
testing, where informed consent must be obtained, oral ﬂuids may be used. Urine is the only
other specimen  (besides blood) routinely collected at some clinics where unlinked anonymous
testing could be conducted.
 
Advantages
 
• Do not require a trained technician for specimen collection and processing.
• Do not require contact with possibly contaminated laboratory materials, e.g., used
needles or lancets that need biohazard waste facilities.                         
• Oral ﬂuids can be collected in a variety of ﬁeld settings, including nonclinical settings. 
• Oral ﬂuid collection may be more acceptable to hard-to-reach populations than
specimen collection requiring venipuncture or ﬁnger stick. Therefore, a greater
percentage of the target population may agree to be tested. 
 
Disadvantages
 
• Urine EIA tests are less sensitive and speciﬁc than blood-based tests  (Martinez et al.
1999). 
• Urine specimens must be tested at a laboratory (EIA); no rapid test is currently available.
• Oral ﬂuid collection may require special equipment.
• Currently available testing technologies for use with these specimens are limited.
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• Are likely to cost more than using serum or plasma.
• May require an additional specimen (e.g., blood) for conﬁrmation.
• Cannot be used to perform additional testing for special studies (e.g., HIV-1 vs. HIV-2,
HIV subtyping, antiretroviral resistance).
 
3.2 Collecting, Processing, and Storing Blood Specimens  
 
3.2.1 Whole Blood, Serum, and Plasma
 
Blood needed for an HIV test can be collected either by venipuncture (whole blood, serum,
plasma) or by ﬁnger stick (whole blood). 
 
3.2.1.1 Processing Blood Collected by Venipuncture
 
To collect blood by venipuncture, follow local clinical or laboratory procedures. See the
Appendix and Section 6.3 for information on safety procedures.
The following steps are recommended for processing blood collected by venipuncture
(National Committee for Clinical Laboratory Standards [NCCLS] 1998): 
1. Collect up to 10 ml of blood from the patient’s vein into a sterile 10 ml tube. 
 
For serum
 
, blood is collected in a red-top tube (without anticoagulants). 
 
For plasma
 
, blood is collected in a purple-top tube (with anticoagulants, e.g., EDTA). 
For safety reasons, the use of an evacuated blood collection system (e.g., Vacutainer
 
®
 
tube) is recommended. (Note: Obtaining an additional tube of blood during routine
blood collection solely for the purpose of unlinked anonymous testing is considered
unethical and is not advised.)
If the blood specimen will not or cannot be processed immediately (e.g., no centrifuge is
available), collect the blood in a purple-top tube with EDTA. Let the blood stand for at
least 20-30 minutes, and then remove plasma carefully with a pipette so as not to get
too many red blood cells. Process (see Step #3) and test within 24 hours to avoid hemol-
ysis of the specimen. A dried blood spot can also be prepared at this time using antico-
agulated blood. 
 
recommendation
 
Blood (whole blood, serum, plasma) is the preferred specimen for testing because it has a 
higher concentration of HIV antibodies than urine or oral ﬂuids. It also allows for additional 
routine testing, including syphilis, hepatitis B, and hepatitis C, and for special studies of HIV 
type and subtype and antiretroviral resistance.
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2. Centrifuge the specimen to separate the serum (without EDTA) or plasma (with EDTA). If
blood is collected for serum, allow the blood to stand for at least 20-30 minutes so that
a clot will form before centrifuging. In general, the specimen should be centrifuged at
300-400 g or 1,200 to 1,500 RPM for 10 minutes (Lennette et al. 1985).
3. After the specimen is centrifuged or has had time to separate, use a clean pipette (do not
pour) to remove an aliquot of 0.5 to 2.0 ml off the top layer. Transfer it to another sterile
labeled tube (plastic, not glass) or cryovial (1.5-2.0 ml with screw cap) and tighten the
cap. The specimen is ready for storage and testing. 
 
3.2.1.2  Storing Serum and Plasma Collected by Venipuncture
 
To store serum and plasma, consider the following (NCCLS 1990):
• Make sure the cap is tight on the labeled cryovial or plastic tube. (Do not use glass tubes
for storing specimens.) Place the cryovials in a cardboard freezer box with a partitioned
insert.
• If the specimens are to be transported to the testing laboratory, immediately pack the
box upright in a cooler containing cold packs to produce an ambient temperature of 4ºC
within the cooler. If cold packs are not available, serum specimens can remain at room
temperature for up to 3 days. Longer periods at room temperature may result in
bacterial overgrowth and breakdown of the specimen. 
• If specimens are held at the collection site for longer than 3 days prior to shipment to
the laboratory where testing will be performed, freeze specimens at -20ºC in a non-
frost-free freezer. For long-term storage, specimens should ideally be frozen at -70ºC in
a non-frost-free freezer. 
• Limit the number of freeze/thaw cycles to ﬁve because multiple thaws will affect
antibody levels and therefore test results.
 
3.2.1.3  Collecting Blood by Finger Stick
 
Blood collected by ﬁnger stick can be used to perform a rapid test or make a dried blood
spot on ﬁlter paper. A dried blood spot may be preferred in rural settings and nonclinical settings,
which often do not have trained phlebotomists and laboratory facilities with appropriate equip-
ment (e.g., centrifuges). 
1. To obtain a ﬁnger-stick specimen, massage the ﬁnger (preferably the middle or ring ﬁn-
ger), which will cause blood to accumulate at the tip of the ﬁnger. 
2. Cleanse the ﬁnger pad (not just the tip or side of the ﬁnger) with 70% isopropyl
(rubbing) alcohol. Wipe away alcohol with sterile gauze pad.
3. Use a sterile lancet to ﬁrmly prick the ﬁnger pad. Wipe the ﬁrst drop of blood off the
ﬁnger with sterile gauze before collecting subsequent blood to place on the rapid test
apparatus or on the ﬁlter paper for the dried blood spot. If the original puncture is
inadequate, the same site should not be reused; another site or ﬁnger should be used.
Avoid milking or squeezing the puncture as this may cause hemolysis of the specimen
and could invalidate the test result (NCCLS 1999). The ear lobe may be pricked instead
of the ﬁnger. 
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3.2.1.4   Preparing and Storing a Dried Blood Spot for an HIV Test
 
Blood from a ﬁnger or ear-lobe stick can be used to make dried blood spots (George et al.
1989). Although ﬁnger stick is the most typical method, dried blood spots can also be obtained by
using blood collected in a tube with an anticoagulant (NCCLS 1997). Dried blood spots have the
advantage of being easily transported, without the need for a cold chain.
1. Apply blood directly from a ﬁnger or a pipette onto special ﬁlter paper (Schleicher and
Schuell Grade 903 Filter Paper or Whatman BFC 180 paper). The paper may come with
preprinted circles that will contain approximately 100 
 
µ
 
L blood when completely ﬁlled.
If the paper does not have preprinted circles, place blood on the paper so that it makes a
circle with a 1.5 cm diameter. Allow the blood to soak through and ﬁll the entire circle.
Caution: If the blood does not saturate the ﬁlter paper, that paper should not be used. 
2. Label the side of the ﬁlter paper with a code after the ﬁlter paper is saturated with blood
(circle is ﬁlled). 
3. Suspend ﬁlter paper strips containing the ﬁlled circles during the drying process to
allow air to circulate around the paper. Stands for holding the strips are commercially
available. However, strips may also be dried by placing them between two books (taping
the edges of the strips to the books with sticky tape) on a table or a laboratory bench top
so that the blood-containing part of the paper is not in contact with the surface of the
table or laboratory bench top. Be sure not to get tape on the blood spot. 
4. Let the blood spots air dry at room temperature for at least 4 hours (and for at least 24
hours in humid climates). Do not heat or stack blood spots, and do not allow them to
touch other surfaces while they are drying. 
5. After blood spots have been adequately dried, wrap the strip in one sheet of glassine
paper or plastic to prevent carryover of specimen from one sheet to another. 
6. Place the wrapped strips in a gas-impermeable bag with desiccant and humidity
indicator cards. Approximately 20 strips may be placed in each bag. Bags may be kept
at room temperature for up to 30 days and then stored at 4ºC for up to 90 days. If the
dried blood spots in their plastic bags are to be stored longer than 90 days, they should
be maintained at -20ºC (George et al. 1989). Properly stored dried blood spots have been
shown to be stable for at least 2 years. The bags should be placed in a sturdy envelope
for shipment (Knudsen et al. 1993).
 
3.3 Collecting and Storing Urine and Oral Fluids
 
3.3.1 Collecting Urine and Oral Fluids
 
For specimen collection, follow test instructions, as well as local laboratory procedures. See
Section 6.3 for information on safety procedures.
 
3.3.1.1 Urine
 
A variety of EIA protocols exist for using urine specimens; however, no rapid tests are
available at this time for use with urine specimens. 
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A few important considerations when collecting urine are
• A minimum of 200 
 
µ
 
L of urine is usually required for use with a urine-based EIA test
kit.
• Specimen can be collected at any time of day and need not be midstream.
• A preservative may be added to the specimen for storage, although it is not required.
 
3.3.1.2 Oral Fluids
 
Oral ﬂuids can be used with both modiﬁed EIAs and rapid tests. Rapid tests using oral ﬂuids
are currently under ﬁeld evaluation.
The following general steps to collect a specimen are provided: 
1. Use a specially treated absorbent pad attached to a plastic stick (usually provided by the
test kit manufacturer).
2. Place the pad in the person’s mouth against the inner cheek for the length of time spec-
iﬁed in the manufacturer’s instructions. Then place the pad into a vial containing a pre-
servative solution (usually provided by the test kit manufacturer). 
Due to the test complexity, oral ﬂuid specimens collected for EIAs are sent to a national
laboratory for analysis. 
 
3.3.2 Storing Urine and Oral Fluids
 
Urine specimens should be placed in plastic cryovials containing a preservative. Urine spec-
imens with a preservative may be stored up to 1 year at 4º-8ºC. Urine specimens for HIV testing
must not be frozen.
Oral ﬂuid specimens can be stored from 4º to 37ºC for a maximum of 21 days (including
the time for shipping and testing). Oral specimens should be refrigerated during shipment. Speci-
mens can be frozen (-20ºC) for a limited time (approximately 6 weeks). Once thawed, they can be
refrozen once. Consult the test kit insert prior to testing for more speciﬁc storage information.
 
3.4 Labeling and Logging Collected Specimens
 
3.4.1 Labeling Specimens
The plastic tube, cryovial, or ﬁlter paper containing the specimen must be labeled with a
code at the time of collection and processing. If labels are used, make sure the label is placed on
the side of the tube, not on the cap. Preprinted cryolabels designed to adhere during freezer stor-
age should be used when specimens are stored in cryovials. Surveillance coordinators should pro-
vide the ﬁeld staff responsible for specimen collection with a series of labels or permanent
markers and the codes to be used.  
For unlinked anonymous testing, label the tube only with a new code unlinked to personal
identifying information (see Figure 2.1). 
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3.4.2 Logging Specimens
A separate laboratory logbook or line listing for surveillance activities should be main-
tained to record HIV test results by the corresponding code. The logbook should be accessible
only to laboratory and surveillance staff; it should be secured in a locked drawer or cabinet when
not in use to ensure the conﬁdentiality of the persons’ test results as well as their participation in
surveillance activities (see Figures 2.1, 2.2).
For unlinked anonymous testing, the logbook or line listing should contain only the new
codes and corresponding HIV test results; no personal identifying information on the patients
whose specimens are tested should be included. HIV test results can be matched by the new code
to the demographic information abstracted earlier on the surveillance form (see Figure 2.1). 
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4.0 Current HIV Testing Technologies and 
Strategies Used in Surveillance
4.1 HIV Testing Technologies
4.1.1 Overview of HIV Testing
HIV testing technologies can currently identify
• Antibodies to HIV (e.g., EIA, rapid test, Western blot, immunoﬂuorescence assay,
particle agglutination)
• Speciﬁc HIV antigens (e.g., EIA, antigen testing)
• HIV viral nucleic acid (e.g., by polymerase chain reaction or other techniques)
• HIV (by viral culture) 
For surveillance as well as diagnostic purposes in developing countries, technologies that
identify HIV antigen, viral nucleic acid, or HIV itself are expensive, technically more difﬁcult,
and more often affected by laboratory error. In most industrialized countries, current diagnostic
testing procedures use an EIA to screen a specimen, and if it is reactive, the result is conﬁrmed by
testing the specimen with a Western blot. However, studies have shown that the latest generation
of EIAs and rapid tests are as reliable for conﬁrmation as Western blots. In addition, compared
with Western blots, EIAs and rapid tests are less expensive, do not require as high a level of tech-
nical expertise to perform and interpret, and produce fewer indeterminate results (Tam 1999;
Stetler et al. 1997). Therefore, UNAIDS and WHO recommend alternative testing strategies using
combinations of EIAs or rapid tests to conﬁrm initial positive tests (UNAIDS 1997). The ﬁrst test
(screening test) should be highly sensitive to provide reliable detection of antibodies in a speci-
men. The second test (conﬁrmatory test) should be highly speciﬁc to conﬁrm that the specimen
truly contains antibodies speciﬁc to HIV (UNAIDS/WHO 1999).
Most EIAs and rapid tests contain antigens to both HIV-1 and HIV-2 and therefore can
detect antibodies to both HIV types. However, most tests do not distinguish between HIV-1 and
HIV-2. EIAs and rapid tests are recommended for both HIV surveillance and diagnostic purposes
summary
Current Testing Technologies and Strategies
• Testing Technologies (Enzyme Immunoassays and Rapid Tests)
Test Characteristics and Applications
General Steps for Performing Tests
• UNAIDS and WHO Testing Strategies I, II, III
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because they are the most accurate and cost-effective. UNAIDS and WHO have deﬁned four cate-
gories of complexity for EIAs and rapid tests: (1) No additional equipment or laboratory experi-
ence is required; (2) Reagent preparation or a multistep process is required; (3) Speciﬁc skills such
as diluting are required; and (4) Equipment and skilled laboratory technicians are required
(UNAIDS/WHO 1998).
4.1.2 Enzyme Immunoassays 
4.1.2.1 General Description
EIAs rely on a primary antigen-antibody interaction and can use whole viral lysate of HIV
or one or more antigens from the virus. Early EIAs produced more false-positive HIV antibody
results than the current third generation of EIAs (Tam 1999). The antigen preparations in early
EIAs were more cross-reactive with components from the host cell (the human lymphocyte cell
lines in which the virus was grown). Therefore, specimens initially found reactive when screened
with an EIA were always conﬁrmed with a Western blot. However, second and third generation
EIAs have shown marked improvement in speciﬁcity, as well as sensitivity, making them candi-
dates for conﬁrmatory assays. The use of recombinant proteins and synthetic peptides also
improved the sensitivity, which reduced the nonreactive period after initial infection with HIV
and permitted earlier detection of an infection (UNAIDS/WHO 1999). Most HIV EIAs contain anti-
gens to HIV-1 and HIV-2 and have been optimized to detect antibodies to both (Tam 1999;
UNAIDS/WHO 1999).
4.1.2.2 Characteristics of EIAs
EIAs are best performed at a regional or national laboratory since they require well-trained
and skilled laboratory technicians, technologically advanced equipment (incubators, washers, and
spectrophotometers) that requires maintenance, and a constant source of electricity. EIAs are most
efﬁcient for laboratories that process a large number of specimens (100 or more) daily or for
batch testing, which is common in HIV sentinel surveillance activities. Because of test design,
they are not suitable or cost-effective to run on a small number of specimens. However, if a labo-
ratory processes at least 50 specimens each day on a regular basis, EIAs may still be more appro-
priate than rapid tests. Because laboratories often batch specimens and run them at one time, the
time before results are available may be from days to 2 or 3 weeks after collection. While this
delay might be of concern for diagnostic purposes, it is not a disadvantage for unlinked anony-
mous testing since results are not provided back to the person, and same-day testing could lead
to identiﬁcation of the person tested. Since EIAs are usually performed at the regional or national
level, quality assurance and quality control measures need to be implemented in only a few labo-
ratories (see Section 6.0). EIAs may have limited application in rural settings where the laboratory
infrastructure and equipment may be insufﬁcient (Table).
recommendation
Of the available testing technologies, EIAs and rapid tests are the most accurate and cost-
effective for both surveillance and diagnostic purposes.
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The cost of an EIA ranges from USD1-2 per test. When considering both direct and indirect
costs (technology, human resources, and equipment requirements), the actual cost may exceed
USD15-20 per test (Brown and Burke 1995). However, if the direct and indirect costs are shared
across all programs (blood screening, diagnosis, and surveillance), a more realistic cost for sur-
veillance activities would be USD4-6.
4.1.2.3 Performing an EIA
EIAs can be performed with serum, plasma, urine, oral ﬂuids, or dried blood spots (once
eluted). They can take from 2 to 4 hours to perform (including specimen preparation and dilution)
and an additional 3 to 4 hours if a screening result has to be conﬁrmed. Manufacturer’s instruc-
tions provided with the speciﬁc EIA used should be followed.
General steps for performing an EIA include
1. Dilute the specimen in the specimen buffer and put it in a microwell plate containing
HIV antigen already bound to the plate.
2. Incubate the plate as per protocol and then wash as indicated.
3. Add antihuman immunoglobulin-enzyme conjugate, which will react with the HIV-
speciﬁc antibody, if present.
4. Incubate.
5. Wash the plate, add the enzyme substrate, and incubate as prescribed.
6. Add a stopping solution to terminate the enzyme reaction, and read the absorbance of
the solution in a spectrophotometer.
A positive reaction has occurred if the specimen in the specimen well changes color or
becomes colored, which indicates the presence of HIV-speciﬁc antibody in the specimen. The
reaction is best read quantitatively with an EIA plate spectrophotometer.
The following are critical to the success of conducting an EIA:
• Use of test kits that have not expired
• Calibrated and well-maintained equipment
• Adherence to incubation and dilution times described in the manufacturer’s instructions
• Use of deionized water
• Use of a spectrophotometer to read results accurately and objectively
• Training with the technology being used
• Consistent source of power without outages that would affect the storage of reagents or
the functioning of equipment
recommendation
EIAs are efﬁcient for laboratories that process large numbers of specimens daily, as is common 
when conducting HIV sentinel surveillance. 
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4.1.3 Rapid Tests
4.1.3.1 General Description
Interest in the development of HIV antibody tests that provide same-day results and do not
require reagents or equipment not contained in the kit led to the currently available HIV rapid
tests. Current rapid tests are based on four immunologic principles: particle agglutination, immu-
nodot (dipstick), immunoﬁltration (ﬂow-through device), and immunochromatography (lateral
ﬂow) (UNAIDS/WHO 1998). Most HIV rapid tests contain antigens to HIV-1 and HIV-2 and detect
antibodies to both (Tam 1999; UNAIDS/WHO 1999). A positive test result is indicated by clump-
ing, a spot, dot, or line, depending on the test format. The sensitivity and speciﬁcity of the latest
generation of rapid tests are similar to those of EIAs. Many rapid tests are under evaluation or are
currently in use in developing countries for screening, diagnostic, and surveillance purposes.
4.1.3.2 Characteristics of Rapid Tests
Rapid tests are useful for small laboratories that routinely perform fewer than 100 HIV tests
per day, for laboratories without electricity or equipment, and for geographic areas with limited
laboratory infrastructure. In some instances, even if a laboratory performs more than 100 tests
per day but only during a limited time in a year, rapid tests may be more appropriate than EIAs.
A result can usually be obtained in less than 45 minutes, and it is easy to interpret. However,
some training is required to correctly perform the test and interpret the results. The test kits gen-
erally contain all reagents needed to run the assay: no additional reagents or equipment are
required. Many rapid tests do not require electricity, special equipment, refrigeration, or highly
skilled staff, although a few require refrigeration for heat-sensitive reagents.
Rapid tests may be appropriate for linked conﬁdential testing among hard-to-reach popula-
tions (e.g., injection drug users, female sex workers) or geographically remote populations. In
these populations, opportunities for provision of results may be limited after the initial encounter;
therefore, testing (screening and conﬁrmatory) may need to be performed on site on the same day
as specimen collection (Respess, Rayﬁeld, and Dondero 2001). If HIV test results are to be
returned to the person tested, a conﬁrmatory test is required (e.g., another rapid test or EIA). 
Rapid tests generally cost between USD1-3, a slightly higher cost per test than an EIA.
However, rapid tests may be more cost-effective than EIAs if the additional costs of conducting
an EIA are considered (e.g., equipment, laboratory infrastructure, technician training). Since there
are very few steps in performing a rapid test, there is less chance for error than with EIAs. In
addition, most rapid tests include an internal quality control. However, when using rapid tests,
quality assurance and external quality control measures need to be developed and implemented
at all sites that are using them (Table).
recommendation
Rapid tests are useful in settings where EIAs are not feasible or practical and in geographic 
areas with limited laboratory infrastructure. Rapid tests may be appropriate for hard-to-reach 
populations (e.g., injection drug users, female sex workers) or geographically remote 
populations, for whom HIV test results may need to be provided on site on the same day as 
specimen collection.
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aThe cost of a testing technology will be affected by the direct and indirect costs.
bUNAIDS/WHO’s four categories of complexity for HIV antibody tests: (1) No additional equipment or laboratory 
experience is required; (2) Reagent preparation or a multistep process is required; (3) Speciﬁc skills such as diluting are 
required; and (4) Equipment and trained laboratory technician are required (UNAIDS/WHO 1998).
cRapid tests using oral ﬂuids are under evaluation in ﬁeld settings.
EIA, enzyme immunoassay; QA/QC, quality assurance/quality control.
Table.  A Comparison of HIV Testing Technologies: 
Enzyme Immunoassays and Rapid Tests
HIV Testing 
Technology Specimens Advantages Limitations
Costa 
(USD) Complexityb
EIA Serum
Plasma
Dried  blood         
spots 
Oral ﬂuids
Urine
• Can be batched: 
good for >100 
specimens at a time
• Can be 
automated
• QA/QC done at 
national and 
regional 
laboratories: easier 
to control
• Cost per test less 
than cost per rapid 
test
• Identiﬁes 
seroconverters 
earlier:  highly 
sensitive, which 
reduces non-
reactive period
• Not ﬂexible in 
testing (need 
minimum numbers 
ﬁlled for maximum 
efﬁciency)
• Requires skilled, 
trained technicians 
to perform and read 
results
• Requires >2 hours 
for results (if need to 
run two EIAs, >5 
hours)
• Requires special 
equipment
• Requires 
maintenance of 
equipment 
• Reagents must be 
refrigerated
1-2 4
Rapid test Serum
Plasma
Whole blood
Oral ﬂuidsc
• Good for testing 
1 to 100 specimens 
at a time
• Requires minimal 
equipment and 
reagents
• Can be 
performed in a 
clinic (on-site 
testing)
• Highly skilled 
staff not required
• Very easy to 
interpret test results
• Results in < 45 
minutes
• Test kits can be 
stored at room 
temperature 
(increased stability)
• Not good for 
testing >100 
specimens at a time
• The QA/QC is 
performed at 
multiple sites: 
requires more control
• May cost more per 
individual test than 
EIA
• Choice of testing 
strategy may require 
multiple specimens
• Interreader 
variability may 
provide inconsistent 
results with some 
assay formats (e.g., 
particle 
agglutination)
1-3 For tests 
based on 
Immuno-
chromato-
graphy — 1
Dipstick and 
membrane- 
ﬂow-through 
technology 
— 2
Agglutination 
— 3
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4.1.3.3 Performing a Rapid Test
Rapid tests can be performed with serum, plasma, whole blood, and oral ﬂuids. Oral ﬂuid-
based rapid tests are under evaluation in ﬁeld settings. No rapid test is currently available for use
with urine. For some rapid tests, specimen preparation may take as long as 10-20 minutes, while
the simplest rapid tests require no specimen preparation. Thus, conﬁrmed test results can be
obtained in less than 45 minutes after the specimen is applied to the device or strip. Manufac-
turer’s instructions provided with the test kit should be followed. Most results are easy to read
and are indicated by clumping, a spot, dot, or line, depending on the test format.
The following are critical to the success of conducting a rapid test:
• Use of test kits that have not expired
• Training with the technology being used
• Adherence to manufacturer’s instructions
• Correct interpretation of results by person reading results
4.2 HIV Testing Strategies for Surveillance
UNAIDS and WHO recommend three criteria for choosing an HIV testing strategy (i.e.,
selecting appropriate HIV testing technologies or a combination of tests) (UNAIDS/WHO 1998):  
1. Objective of the test (surveillance, blood screening, or diagnosis),
2. Sensitivity and speciﬁcity of the test(s) being used, and 
3. HIV prevalence in the population being tested 
After these three criteria are deﬁned, an HIV testing strategy can be selected to maximize
sensitivity and speciﬁcity while minimizing cost. The three HIV testing strategies recommended
by UNAIDS and WHO are described below (Figure 4).
Strategy I:
• Requires one test. 
• For use in diagnostic testing in populations with an HIV prevalence >30% among
persons with clinical signs or symptoms of HIV infection.
• For use in blood screening, for all prevalence rates.
• For use in surveillance testing in populations with an HIV prevalence >10% (e.g.,
unlinked anonymous testing for surveillance among pregnant women at antenatal
clinics). No results are provided. 
Strategy II:
• Requires up to two tests.
• For use in diagnostic testing in populations with an HIV prevalence ≤ 30% among
persons with clinical signs or symptoms of HIV infection or >10% among asymptomatic
persons.
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• For use in surveillance testing in populations with an HIV prevalence ≤ 10% (e.g.,
unlinked anonymous testing for surveillance among patients at antenatal clinics or
sexually transmitted infection clinics). No results are provided.
Strategy III:
• Requires up to three tests.
• For use in diagnostic testing in populations with an HIV prevalence ≤ 10% among
asymptomatic persons.
Figure 4. UNAIDS and WHO HIV Testing Strategies
Strategy III
Diagnosis
A1
A1+ A1–
Negative
Strategy I
Screening/Surveillance
A1
A1+
Positive 
A1–
Negative
A2
A1+A2+
Positive 
A1+A2–
Negative
A3
A1+A2– A3+
Positive 
A1+A2– A3–
Negative
A2
A1+A2+
Positive 
A1+A2–
A =  Assay  (test)
1,2,3 =  Order of assays
+ =  Reactive
–  =  Nonreactive
Strategy II
Surveillance/Diagnosis
A1
A1+
A1–
Negative
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For HIV testing strategies where more than one test may be required (Strategies II and III),
the selection of testing technologies and the order in which they are used (testing algorithm) are
important for obtaining accurate test results. First, the tests should contain different antigens.
Second, the ﬁrst test should have as high a sensitivity as possible, and the second test should
have as high a speciﬁcity as possible. The ﬁrst test is the screening test, so it is ideal to have a
more sensitive test to detect all positives. Because a few false positives will occur, the second test
(conﬁrmation test) needs to be highly speciﬁc to ensure that all truly negative test results are
identiﬁed as negative. In addition, when Strategy II or III is used, tests that can use serum,
plasma, or dried blood spots are recommended so that multiple tests can be performed from a sin-
gle specimen, avoiding collection of additional specimens.  
For rapid tests that use oral ﬂuid or whole blood from a ﬁnger stick, the specimen is placed
directly on the rapid test apparatus; thus, a second specimen must be collected for conﬁrmation if
the ﬁrst test is reactive. Therefore, for testing strategies II and III, it is suggested that, if feasible,
two rapid tests be performed simultaneously on a single oral swab or ﬁnger stick and then ana-
lyzed as if performed sequentially. 
This testing situation may occur when conducting linked HIV testing among hard-to-reach
populations. In this situation, there is only one opportunity during which to obtain informed con-
sent, collect the specimen, conduct the test, and provide the results and adequate counseling to
the person tested. Only rapid tests allow for on-site same-day screening and conﬁrmation. If
blood is the specimen collected, dried blood spots can be prepared for quality assurance purposes
(Respess, Rayﬁeld, and Dondero 2001).
recommendation
When Strategy II or III is used, tests that can use serum, plasma, or dried blood spots are 
recommended so that multiple tests can be performed from a single specimen, avoiding 
collection of additional specimens.  
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5.0 Selection and Evaluation of HIV Testing 
Technologies Used in HIV Surveillance 
Many countries use a variety of different HIV testing technologies and testing algorithms.
For example, the national reference laboratory may screen with a rapid test and conﬁrm with an
EIA while the regional laboratory may use different rapid tests than the national laboratory for
both screening and conﬁrmation. Because of these differences, it is important for the national
surveillance coordinator to document all of the testing technologies and testing algorithms that
are being used in the country. In addition, in order to ensure reliable and comparable surveillance
data over time, the number of testing technologies that are in use in a country should be mini-
mized.
5.1 How to Select Tests
Selecting appropriate HIV testing technologies for use in developing countries may be a
challenge since there may not be a national technical advisory group to review and evaluate
available HIV tests. Therefore, the decision about which test(s) to select may often be made by a
donor agency, may be based on price, or may be made as a result of a manufacturer’s inﬂuence.
summary
Selection and Evaluation of HIV Testing Technologies
• Selection Factors
UNAIDS/WHO Recommendations Regarding Selection of EIAs or Rapid Tests
UNAIDS/WHO Annual Report of Operational Characteristics of Available Tests in 
Laboratory Settings
Operational Characteristics of Tests in the Field
Country Conditions
• Country Evaluation of Selected Tests
Evaluation of Tests at the National Reference Laboratory, Regional Laboratory, and 
Settings Where They Will Most Likely Be Used
recommendation
It is important for the surveillance coordinator to document all of the testing technologies and 
testing algorithms that are being used in the country.
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Instead, if the laboratory infrastructure at the national level is sufﬁcient, countries should evalu-
ate the performance of HIV testing technologies in their laboratory settings. However, the evalua-
tion of testing technologies in a country can be limited by the high cost of equipment and lack of
technical expertise, as well as insufﬁcient capabilities to process specimens and then transport
them to the national laboratory. 
If it is not feasible to conduct a country evaluation, a country should review the selection
factors below and then either select a test(s) from the UNAIDS/WHO list of currently available
HIV tests or select a test based on evaluations, preferably in the region, by another independent,
noncommercial source (Figure 5).
Figure 5. How to Select an HIV Test
* Determine the sensitivity and speciﬁcity of selected HIV tests in clinic and laboratory settings.
**Select the best test(s) and, for Strategies II and III, order of tests.
Strategy II Strategy III Strategy I
Select HIV testing strategy
      Select tests for evaluation on the basis of:
•   UNAIDS/WHO recommendations regarding when to use rapid tests and/or EIAs
•   UNAIDS/WHO operational characteristics (e.g., accuracy) of commercially available tests
•   Operational characteristics of tests in the field
•  Country  conditions
Perform country evaluation*
Yes No
Select test(s) based on evaluation results** Select test(s) from UNAIDS/WHO list**
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Selection Factors
The ﬁrst decision in selecting HIV testing technologies should be which testing format will
be used (EIA, rapid test, or a combination of the two). Then, the operational characteristics of the
testing technologies should be reviewed in relation to country conditions: the laboratory infra-
structure, the availability of skilled laboratory personnel, and the existence of quality assurance
and control measures. 
• UNAIDS/WHO Recommendations Regarding Selection of EIAs or Rapid Tests.
UNAIDS and WHO recommend rapid tests instead of EIAs in geographically remote
areas, areas with little or no laboratory infrastructure, and small hospitals that perform
fewer than 100 tests per day. In these situations, rapid tests are preferred because they
are fast and easy to perform, and most have a longer shelf life than reagents for EIAs
(UNAIDS/WHO 1998). Rapid tests are ideal for use at the local level because of their
simplicity and low indirect cost (especially for equipment and maintenance of
equipment). UNAIDS and WHO recommend EIAs for areas with good laboratory
infrastructure and trained staff and for hospitals that perform 100 or more tests per day,
as EIAs are very efﬁcient for batched testing and easily implemented in laboratories at
the national or regional level (UNAIDS/WHO 1998).
• UNAIDS/WHO Annual Report of Operational Characteristics of Commercially
Available HIV Tests.  UNAIDS and WHO publish an annual report of operational
characteristics of commercially available HIV tests, which includes evaluations of the
tests’ sensitivity and speciﬁcity, ease of performance, suitability for use in small
laboratories, and cost (UNAIDS/WHO 1999). Copies of this report may be obtained by
contacting UNAIDS or WHO at unaids@unaids.org or publications@who.int. As
described in Section 4.2, a highly accurate test is recommended so that the percentage
of false negatives and false positives is reduced. The revised recommendations of
UNAIDS and WHO state that HIV antibody tests used for surveillance need to have a
speciﬁcity of at least 95% (UNAIDS/WHO 1998). Currently, most tests have a speciﬁcity
of 98% or higher, but the actual sensitivity and speciﬁcity of the tests when conducted
in the ﬁeld may vary by the geographic origin of specimens (UNAIDS 1997).
• Operational Characteristics of the Tests in the Field.  It is important to consider the
selected tests’ operational characteristics in the country in which they will be used.
Important characteristics include ease of performance, cost per test, storage
requirements, normal shelf life of the product, equipment and maintenance required,
training of personnel, and regular availability of the tests from the manufacturers
(UNAIDS 1997).
recommendation
Before tests are selected for use in a country, the country should evaluate the tests’ accuracy 
and operational characteristics in that country or, if this is not possible, select tests on the basis 
of evaluation by an independent, noncommercial source.
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• Country Conditions.  Country conditions that will inﬂuence test selection include
number of tests performed daily, staff expertise, technological skills of laboratory
personnel, test costs, laboratory infrastructure, existence of a reference laboratory,
quality control and quality assurance measures in the laboratory, storage conditions
(temperature and refrigeration controls), and laboratory logistics (e.g., availability of
supplies, continued source of electricity).
5.2 Country Evaluation of Selected Tests
Ideally, the selected HIV testing technologies should be evaluated in the country to
(1)determine commercially available HIV tests’ sensitivity and speciﬁcity in the country, and
(2)validate the performance of different testing algorithms based on the results of the sensitivity
and speciﬁcity of the tests evaluated (Branson 2000). A three-phase approach may be used for a
country evaluation (Box 3). The ﬁrst phase is conducted at the national reference laboratory to
determine the sensitivity and speciﬁcity of the new test(s) under ideal laboratory conditions. In
Phases II and III, specimens are collected prospectively. In the second phase, the specimens are
collected at a few regional clinics and evaluated at regional laboratories. In the third phase, the
specimens are collected and evaluated under the ﬁeld conditions in which they will be used.
This type of three-phase evaluation has been conducted in Honduras and in Uganda (Stetler
et al. 1997; Downing et al. 1998). In Honduras, seven rapid tests were evaluated in Phase I by
testing 600 specimens stored at the national reference laboratory. Five tests were selected, based
on their sensitivity and speciﬁcity and ease of performance, to be evaluated prospectively in
Phase II (n=900). Three of the ﬁve tests were then further evaluated prospectively in Phase III at
rural hospitals and clinics. The positive and negative predictive values were calculated for the dif-
ferent testing algorithms using the three tests to determine which testing algorithm was most
appropriate. A general outline of three phases for a country evaluation is provided in Box 3;
however, the outline would need to be adapted and expanded upon for speciﬁc country evalua-
tions.
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*Testing technologies that use only whole blood or oral ﬂuid can be evaluated only in Phases II and III.
Adapted from Stetler et al. 1997
Box 3. General outline for a country evaluation of HIV testing technologies
Phase I:  Retrospectively evaluate the sensitivity and speciﬁcity of selected tests at the 
national reference laboratory.
• Select approximately 500 serum or plasma specimens (approximately 250 HIV antibody-
positive and 250 HIV antibody-negative) from specimens already collected and stored frozen 
(e.g., specimens collected from surveillance activities) or from blood stored at blood banks.
• Prior to the evaluation of the tests, create a proﬁciency panel of approximately 25 HIV 
antibody-positive and 25 HIV antibody-negative specimens to evaluate the proﬁciency of the 
technicians performing the tests. Have the technicians who pass proﬁciency testing test the 
selected specimens, masked to the serostatus, using the current testing algorithm and the 
selected tests.* The current testing algorithm should be considered the “gold” standard against 
which the selected tests are evaluated. Determine the sensitivity and speciﬁcity of the selected 
tests.
Phase II:  Prospectively evaluate the selected tests at the regional laboratories.
• Assuming adequate performance (e.g., sensitivity, speciﬁcity, ease of performance) of the 
selected tests in Phase I, prospectively evaluate the selected tests and current tests at a few 
representative regional laboratories and hospitals in the country. Approximately 100 HIV 
antibody-positive specimens and 200 HIV antibody-negative specimens per site (in total, 600- 
900 specimens) should be collected. 
• Each specimen should be given a unique code so that it can later be matched with 
corresponding demographic information collected at the particular site. One possible method 
of specimen selection is the following. Those specimens found to be antibody-positive using 
current tests should be tested with the selected tests. For each antibody-positive specimen, the 
next two antibody-negative specimens should be tested until 100 positive and 200 negative 
test results are obtained.
• Blood should be tested using the selected tests, following manufacturers’ instructions, and 
should also be tested using the current tests and testing algorithm. Only results from tests 
currently being used in the country’s testing algorithm should be returned to the person; 
results from tests under evaluation should not be returned.
• The HIV test results obtained from the current testing algorithm should be considered the 
“gold” standard against which the selected tests and the selected testing algorithm(s) should 
be evaluated to determine the sensitivity and speciﬁcity of the selected tests. Based on the 
sensitivity and speciﬁcity of the selected tests in this phase, select two to three tests for 
evaluation in Phase III.
Phase III:  Prospectively evaluate the selected tests at settings where they will most likely be 
used.
• Prospectively collect blood specimens from a total of 500-900 persons at four to six settings 
where testing with the selected tests is most likely to be performed. The goal is to have at least 
50 HIV-positive specimens per site. This is best done in areas with high HIV prevalence.
• Follow the same selection procedures at the settings as described in Phase II.
• Determine the speciﬁcity and sensitivity of the selected tests and selected testing algorithms 
and compare them to those obtained using the country’s current testing algorithm. On the 
basis of results of the evaluation of the selected tests and of the selected testing algorithms, 
recommend HIV testing technology(ies) and a testing algorithm for the country.
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6.0 Laboratory Quality Assurance and 
Safety
Reliable and reproducible HIV testing over time is an important component of HIV serosur-
veillance. Having highly accurate HIV tests does not necessarily guarantee reliable laboratory
results. Many processes take place from the time the specimen arrives in the laboratory until the
results are recorded, during which time errors can occur (UNAIDS/WHO 1996). Therefore, the
ongoing process of monitoring the laboratory system, both internally and externally, is essential.
Quality assurance is the dynamic and ongoing process of monitoring a system for reliability and
reproducibility of results that permits corrective action when established criteria are not met. 
6.1 National Quality Assurance
Countries should require that laboratories at all levels (e.g., HIV laboratories in hospitals,
blood transfusion services, and private HIV laboratories) participate in an external quality assur-
ance of their performance. The national reference laboratory, in collaboration with the national
AIDS program, should monitor the effectiveness of the participating laboratories’ quality assur-
ance systems to identify any laboratory that might require further training or other required
action. 
The most common method for external quality assurance of a laboratory’s performance is
proﬁciency testing (UNAIDS/WHO 1996). The national reference laboratory should send to all
participating laboratories a proﬁciency panel of approximately six specimens to identify as HIV-
positive or HIV-negative. This panel should contain HIV-negative and HIV-positive (weak to
strong) specimens representative of the HIV strains circulating in a country and of the different
stages of HIV infection (UNAIDS/WHO 1996). Proﬁciency testing should be done once or twice
each year. In geographic areas with limited laboratory infrastructure, laboratories can prepare a
summary
Laboratory Quality Assurance and Safety
• National Quality Assurance
Proﬁciency Testing
• Laboratory Quality Assurance
Preanalytical Phase
Analytical Phase
Postanalytical Phase
• Safety
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dried blood spot on ﬁlter paper to be tested at the national reference laboratory for quality con-
trol purposes. External quality assurance for the national reference laboratory may be provided
by an independent laboratory (e.g., a university) or by one of WHO’s regional quality assurance
programs.
A quality assurance system can help create good national laboratory practices using stan-
dard procedures and will also allow for exchange of information between laboratories (UNAIDS/
WHO 1996). It is also important to provide feedback to the participating laboratories regarding
their evaluations. Elements of the quality assurance system should be included in procedure man-
uals used by laboratory technicians and other laboratory staff. Compliance with such programs
will maximize the reliability and accuracy of test results.
6.2 Laboratory Quality Assurance
Laboratories at all levels (national, regional, and local) that conduct HIV testing should
have a functioning internal quality assurance program. Each laboratory conducting HIV testing
should routinely monitor and assess the quality in the preanalytical, analytical, and postanalyti-
cal phases of the testing process.
6.2.1 Preanalytical Phase
The preanalytical phase encompasses the following components:
• Training
• Laboratory safety
• Number of trained personnel available and capable of performing HIV testing
• Specimen collection, labeling, and transport conditions
• Treatment of specimens before testing
• Sources and types of specimens tested
• Number of specimens tested
• Selection of test kits 
• Expiration dates of test kits. Kits need to be used before expiration dates, which are
typically indicated on the side of the test kit packaging. Careful rotation of test kit
stocks (older kits should be used before their expiration dates and before newer kits) will
result in a more efﬁcient use of test kit supplies. 
recommendation
Countries should require that all laboratories at all levels (e.g., national reference laboratory, 
HIV laboratories in hospitals, blood transfusion services, and private HIV laboratories) 
participate in an external quality assurance of a laboratory’s performance.
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• HIV test kit reagents. Reagents must be stored at the appropriate temperature as
speciﬁed in the product insert provided by the manufacturer. Certain reagents (e.g.,
conjugates for EIAs) are likely to require refrigeration; other test kit components may
require only storage at room temperature. 
6.2.2 Analytical Phase
The analytical phase encompasses the testing process itself. Some of the components to be
reviewed by the quality assurance program include
• Specimen processing and storage
• Written procedure manual
• Reagent preparation
• Testing performance
• Performance and maintenance of equipment (e.g., spectrophotometers, washers)
• Correct use of reagents
• Inclusion of internal quality controls in the test kits
• Quality control monitoring procedure
6.2.3 Postanalytical Phase
The postanalytical phase encompasses all that occurs after testing including
• Interpreting results 
• Transcribing results, e.g., recording results on the correct identiﬁer code
• Entering data into the tracking system (computer or hard copy)
• Maintaining records 
• Reviewing quality control
6.3 Safety Procedures
Safety precautions are essential and should be followed at all points in the testing process–
from specimen collection to testing, storage, and disposal of biohazard wastes–so as to minimize
occupational risk. See WHO, 1991, and CDC, 1988, for further recommendations on safety pre-
cautions. Precautions for the prevention of transmission of HIV and other blood-borne pathogens
are summarized in the Appendix. For information about postexposure prophylaxis, consult the
country’s national AIDS control program. 
Proper disposal of all contaminated laboratory waste is essential (WHO 1991). All contami-
nated waste in the clinic and laboratory should be decontaminated before disposal; this includes
specimens of body ﬂuids, broken glassware, and containers of contaminated needles (Richmond
and McKinney 1993). Methods to decontaminate all contaminated waste (e.g., autoclaving, chem-
ical disinfecting, incinerating) should be in place. Materials that are decontaminated or disposed
of outside the laboratory should be placed in a strong, leak-proof container prior to transporting
them outside the laboratory.
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Appendix. Universal Precautions for 
Prevention of Transmission of 
HIV, Hepatitis B Virus, and Other 
Bloodborne Pathogens in 
Health-Care Settings
The risk of nosocomial transmission of HIV, HBV, and other bloodborne pathogens can be
minimized if health-care workers use the following general guidelines: 
1. Take care to prevent injuries when using needles, scalpels, and other sharp instruments
or devices; when handling sharp instruments after procedures; when cleaning used
instruments; and when disposing of used needles. Do not recap used needles by hand;
do not remove used needles from disposable syringes by hand; and do not bend, break,
or otherwise manipulate used needles by hand. Place used disposable syringes and nee-
dles, scalpel blades, and other sharp items in puncture-resistant containers for disposal.
2. Use protective barriers (e.g., rubber gloves) to prevent exposure to blood, body ﬂuids
containing visible blood, and other ﬂuids to which universal precautions apply. The type
of protective barrier(s) should be appropriate for the procedure being performed and the
type of exposure anticipated. 
3. Immediately and thoroughly wash hands and other skin surfaces that are contaminated
with blood, body ﬂuids containing visible blood, or other body ﬂuids to which universal
precautions apply.
Glove Use for Phlebotomy
Gloves should reduce the incidence of blood contamination of hands during phlebotomy
(drawing blood samples), but they cannot prevent penetrating injuries caused by needles or other
sharp instruments. In universal precautions, all blood is assumed to be potentially infective for
bloodborne pathogens, but in certain settings (e.g., volunteer blood donation centers), the preva-
lence of infection with some bloodborne pathogens (e.g., HIV, HBV) is known to be very low.
Institutions that judge that routine gloving for all phlebotomies is not necessary should
periodically reevaluate their policy. Gloves should always be available to health-care workers
who wish to use them for phlebotomy. In addition, the following general guidelines apply:
1. Use gloves for performing phlebotomy when the health-care worker has cuts, scratches,
or other breaks in his/her skin.
2. Use gloves in situations where the health-care worker judges that hand contamination
with blood may occur, for example, when performing phlebotomy on an uncooperative
patient. 
3. Use gloves for performing ﬁnger and/or heel sticks on infants and children. 
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4. Use gloves when persons are receiving training in phlebotomy. 
5. Use sterile gloves for procedures involving contact with normally sterile areas of the
body. Use examination gloves for procedures involving contact with mucous
membranes, unless otherwise indicated, and for other patient care or diagnostic
procedures that do not require the use of sterile gloves. 
6. Change gloves between patient contacts.
7. Do not wash or disinfect surgical or examination gloves for reuse. Washing with
surfactants may cause "wicking," i.e., the enhanced penetration of liquids through
undetected holes in the glove. Disinfecting agents may cause deterioration. 
8. Use general-purpose utility gloves (e.g., rubber household gloves) for housekeeping
chores involving potential blood contact and for instrument cleaning and
decontamination procedures. Utility gloves may be decontaminated and reused but
should be discarded if they are peeling, cracked, or discolored, or if they have punctures,
tears, or other evidence of deterioration. 
Source:  Centers for Disease Control. Perspectives in disease prevention and health promotion update: Universal precautions 
for prevention of transmission of human immunodeﬁciency virus, hepatitis B virus, and other pathogens in health-care 
settings. MMWR Morb Mortal Wkly Rep 1988; 37(24): 377-88.
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Glossary
Code: A code is used to identify a specimen. It is unique to a specimen and may or may not be
linked to any personal identifying information.
Concentrated epidemic: The epidemic state in which HIV has spread rapidly in a deﬁned subpop-
ulation but is not well established in the general population. (HIV prevalence is consistently 
>5% in at least one deﬁned subpopulation and is <1% in pregnant women in urban areas.)
Enzyme immunoassay (EIA): A type of HIV test that identiﬁes antibodies to HIV. EIAs rely on a
primary antigen-antibody interaction and can use whole viral lysate of HIV or one or more
antigens from the virus. 
Generalized epidemic: The epidemic state in which HIV is ﬁrmly established in the general pop-
ulation. (HIV prevalence is consistently >1% in pregnant women.)
Incidence: The number of new cases of infection or disease that occurs in a deﬁned population
within a speciﬁed time period (i.e., the rate of incidence).
Informed consent: Informed consent is based on the principle that competent persons are entitled
to make decisions regarding their participation in, or acquiescence to, certain events in the
context of a professional relationship between health-care provider and patient/client.
Informed consent protects the person’s freedom of choice and respects his/her autonomy, par-
ticularly with regard to decisions affecting his/her body and health. 
Linked anonymous testing: In linked anonymous testing, a person agrees to have an HIV test,
but the specimen is labeled with a code without a name or identiﬁers that could reveal the
person’s identity. This method is voluntary and requires obtaining informed consent and
making the test results available (with appropriate counseling) to the person tested.
Linked conﬁdential testing: In linked conﬁdential testing, a person agrees to have an HIV anti-
body test with the assurance that the test result will be kept conﬁdential and only selected
health-care providers may be informed. This method is voluntary and requires obtaining
informed consent and discussing the test results with the person. Linked conﬁdential testing
also allows for the collection of more detailed demographic and risk-behavior information.  
Low-level epidemic: The epidemic state in which HIV has never spread to signiﬁcant levels in
any subpopulation, although HIV infection may have existed for many years. (HIV prevalence
has not consistently exceeded 5% in any deﬁned subpopulation.)
Negative predictive value: In HIV testing, the probability that a person with a negative test result
is not infected.
Positive predictive value: In HIV testing, the probability that a person with a positive test result
is infected.
Prevalence: The percentage of persons in a given population with a disease or condition at a
given point in time.
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Proﬁciency panel: Panels containing HIV-negative and HIV-positive (weak to strong) specimens
representative of the HIV strains circulating in a country and of the different stages of HIV
infection. The panel, approximately six specimens, should be sent to participating laborato-
ries once or twice each year for quality assurance testing.
Quality assurance: The dynamic and ongoing process of monitoring a system for reproducibility
and reliability of results that permits corrective action when established criteria are not met. 
Rapid test: An HIV antibody test that is simple, does not require any reagents or equipment other
than what is contained in the kit, and provides fast results.
Second generation HIV surveillance: Developed by the World Health Organization and the Joint
United Nations Programme on HIV/AIDS, second generation HIV surveillance is a  conceptual
framework to improve HIV surveillance. Guidelines for second generation HIV surveillance
suggest approaches to make better use of data to increase and improve the response to the
HIV epidemic.
Sensitivity of a test: A measure of the probability of correctly identifying an HIV-infected per-
son.
Sentinel surveillance: Surveillance conducted through "watchpost" sites that provide access to
populations that are of particular interest or representative of a larger population. 
Serosurveillance: Epidemiologic study or activity based on the detection through serologic test-
ing of presence or absence of HIV antibody. Latent, subclinical infections and carrier states
can thus be detected, in addition to clinically overt cases.
Speciﬁcity of a test: A measure of the probability of correctly identifying an HIV-uninfected per-
son. 
Testing strategy: The use of an appropriate HIV test or combination of HIV tests. The choice of
testing strategy used is based on the objective of the test, the sensitivity and speciﬁcity of the
test, and HIV prevalence in the population being tested.  HIV testing strategies were created to
maximize accuracy and minimize cost.
Unlinked testing: In unlinked testing, a sample of blood originally collected for other purposes is
tested for HIV after all information that could identify the source of the blood is eliminated
from the sample.
Western blot: A type of HIV test, Western blot uses an electroblotting method in which proteins
are transferred from a gel to a thin, rigid support and detected by binding of labeled antibody
to HIV.
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